ProQR Therapeutics (PRQR) to Release Earnings on Thursday

ProQR Therapeutics (NASDAQ:PRQR) is projected to issue its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $6.1180 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 20, 2026 at 12:30 PM ET.

ProQR Therapeutics Trading Up 6.2%

Shares of NASDAQ PRQR opened at $1.89 on Tuesday. The company has a market cap of $198.85 million, a price-to-earnings ratio of -4.02 and a beta of 0.21. ProQR Therapeutics has a 12 month low of $1.07 and a 12 month high of $3.10. The stock has a 50-day moving average price of $1.66 and a two-hundred day moving average price of $2.08.

Institutional Trading of ProQR Therapeutics

Several institutional investors have recently modified their holdings of the business. Ikarian Capital LLC increased its holdings in ProQR Therapeutics by 67.2% in the fourth quarter. Ikarian Capital LLC now owns 1,492,229 shares of the biopharmaceutical company’s stock valued at $3,014,000 after purchasing an additional 600,000 shares during the period. Citadel Advisors LLC lifted its holdings in ProQR Therapeutics by 73.2% during the 3rd quarter. Citadel Advisors LLC now owns 657,012 shares of the biopharmaceutical company’s stock worth $1,399,000 after buying an additional 277,749 shares during the period. Walleye Capital LLC grew its position in shares of ProQR Therapeutics by 11.2% in the 4th quarter. Walleye Capital LLC now owns 591,785 shares of the biopharmaceutical company’s stock valued at $1,195,000 after buying an additional 59,808 shares during the last quarter. Millennium Management LLC grew its position in shares of ProQR Therapeutics by 80.8% in the 4th quarter. Millennium Management LLC now owns 434,991 shares of the biopharmaceutical company’s stock valued at $879,000 after buying an additional 194,369 shares during the last quarter. Finally, Two Sigma Investments LP increased its stake in shares of ProQR Therapeutics by 86.3% in the third quarter. Two Sigma Investments LP now owns 417,300 shares of the biopharmaceutical company’s stock valued at $889,000 after buying an additional 193,260 shares during the period. Institutional investors own 32.65% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on PRQR. Zacks Research raised shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of ProQR Therapeutics in a research note on Thursday, January 22nd. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, ProQR Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $7.67.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.